Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Supernus Pharmaceuticals (SUPN)

Supernus raises executive base salaries, grants stock options and performance units

Neutral Impact 2 of 5 shareholder Written later

Supernus Pharmaceuticals approved annual base salary increases for five executive officers effective January 1, 2026, following its annual compensation review, and granted stock options, RSUs and PSUs. The changes are routine annual compensation actions, and the filing does not describe any change in officer roles.

Key points

  • CEO Jack A. Khattar's base salary rose from $1,036,000 to $1,067,100, with a 2025 bonus of $846,930 and options on 341,610 shares.
  • CFO Timothy C. Dec's base salary rose from $504,900 to $525,100, with a 2025 bonus of $233,894.
  • Option exercise price is $50.20 per share, the closing price on February 18, 2026, the date the grants were approved.
  • Option and RSU awards vest annually in equal increments over four years; PSU vesting depends on performance goals.

The filing

CompanySupernus Pharmaceuticals (SUPN)
Form8-K, current report
Filed with the SECFeb 24, 2026, 4:22 PM ET
Accession number0001356576-26-000007

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 24, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.